Reported about 9 hours ago
Boston Scientific Corporation (BSX) is advancing its position as a leading AI-powered biotech company by integrating artificial intelligence into its medical devices, particularly in cardiology. The recent FDA approval of the FARAPULSE system for treating atrial fibrillation, impacting millions globally, underscores this strategy. The company collaborates with AI platforms to enhance diagnostics and treatment while maintaining strong sales growth. BSX is set to further commercialize AI-driven products, reinforcing its leadership in the medical technology sector.
Source: YAHOO